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ABSTRACT 
 
BACKGROUND: Due to the lacking specificity of symptoms making a correct 
diagnosis can be a challenge in children with medulloblastoma. This can lead to 
prediagnostic symptomatic intervals (PSIs) of several weeks to months. It is unknown 
whether the length of the PSI is associated with an inferior survival outcome in this 
population. 
METHODS: To study the association of PSI with disease stage at diagnosis as well 
as tumor control and survival in children with medulloblastoma, prospectively 
collected data on PSI, clinical, and biological features were analyzed in 224 patients 
diagnosed at the age of 3 - 18 years and treated within the prospective randomized 
multicenter trial HIT’91. 
RESULTS: Patients with lower-stage disease tended towards a longer median PSI 
than those with higher-stage disease (M0 stage, 2.0 months; M1 stage, 2.0 months; 
M2/M3 stage, 1 month; p=0.094. M0/1 stage vs. M2/3 stage; p=0.025). The patient 
group with the longest PSI had the best survival outcome (PSI ≥4.0 months: 10-year 
overall survival rate (OS), 71%; PSI <4.0 months, 10-year OS, 61%; p=0.056). Age at 
diagnosis was positively correlated with PSI (p=0.027). No associations were found 
between PSI and gender, histological subtype, presence of postoperative residual 
tumor, or c-myc and TrkC mRNA expression. 
CONCLUSION: Contrary to a common belief that a longer PSI may adversely affect 
prognosis, a longer PSI was associated with a trend towards lower metastatic stage 
and better survival probabilities. Nevertheless these findings do not obviate the 
importance of a timely diagnosis in pediatric patients with medulloblastoma.
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1. INTRODUCTION 
 
Medulloblastoma is a primitive neuroectodermal tumor of the cerebellum with a 
tendency to metastasize by leptomeningeal spread. It is the most common malignant 
brain tumor in pediatric patients accounting for 20% of all central nervous system 
tumors. Advances in diagnostic, surgical, radiotherapeutic and chemotherapeutic 
methods have led to markedly improved survival outcome in the last decades. 
However, a significant proportion of patients still succumb to their disease.1-2 
 
Making a correct diagnosis can be a challenge due to often non-specific symptoms 
and signs which not only depend on the tumor itself, but also on the patient’s age and 
developmental stage.3 This can lead to prediagnostic symptomatic intervals (PSI) 
(‘diagnostic time lags’) in the range of several weeks to months.4-11 The assumption 
that a longer PSI may result in a more advanced disease stage and/or have an 
adverse impact on tumor control, survival and/or 
neurological/neuropsychological/quality of survival outcome may lead to self-
reproaches from parents and physicians and can result in accusations of medical 
malpractice.12-14 However, available information on the correctness of this 
assumption is insufficient, as studies on PSI in children with brain tumors suffer from 
low patient numbers, retrospective design, heterogeneity of patient, disease, and 
treatment characteristics, and lacking outcome data.4-11, 15-24 
 
To study the association of the PSI with disease stage at diagnosis as well as tumor 
control and survival outcome, we analyzed prospectively collected data on 224 
homogeneously treated patients.
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2. METHODS 
 
2.1. Patients and diagnostic procedures 
 
Between August 1991 and December 1997, 280 patients 3 -18 years of age with 
newly diagnosed medulloblastoma were treated according to the prospective 
randomized multicenter HIT‘91 trial, as previously described.2, 25 Recommended 
staging included pre- and postoperative cranial magnetic resonance imaging (MRI) or 
computed tomography (CT), spinal MRI, and evaluation of cerebrospinal fluid (CSF) 
cytology.26 Central review of histopathology, CSF cytology, and CT/MRI scans was 
recommended. mRNA expression levels of c-myc and TrkC in tumor tissue were 
measured as described.27 Duration of the prediagnostic symptomatic interval (PSI), 
i.e. the interval between the appearance of the first symptom/sign judged as 
unambiguously related to the tumor disease by the treating oncologist, as well as the 
nature of the presenting symptoms and signs were prospectively recorded. A PSI 
value was available for 266 of 280 (95%) patients. The current analysis is restricted 
to those 224 of 280 (80%) patients for whom the PSI value and central 
histopathological review of tumor tissue were available. Complete 
radiology/cerebrospinal fluid staging for metastases was performed in 184 (82%) of 
the 224 study patients.  
 
2.2. Treatment  
 
After obtaining approval of the study protocol from the appropriate ethical committees 
and informed consent from all patients and/or their legal representatives, patients 
were randomly assigned to receive either immediate post-operative radiotherapy 
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(35.2 Gray [Gy] to the craniospinal axis followed by a boost to the posterior fossa to a 
total of 55.2 Gy and to any supratentorial and spinal metastases to 50.0 Gy, with 
concomitant vincristine) followed by ‘maintenance’ chemotherapy (CCNU, vincristine, 
and cisplatin); or immediate post-operative pre-radiation ‘sandwich’ chemotherapy 
(ifosfamide, etoposide, methotrexate, cisplatin, and cytarabine) followed by 
radiotherapy and, in case of non-complete response thereafter, additional 
‘maintenance’ chemotherapy, as previously described.2, 25  
 
2.3. Statistical analyses  
 
Kaplan–Meier estimates and log-rank test were used for overall survival (OS) and 
progression-free survival (PFS) rates (±standard errors), with OS measured from 
primary surgery to death of any cause or last evaluation, whichever came first, and 
PFS measured from primary surgery to first documented progressive disease, to 
death of any cause, or to last evaluation, whichever came first. To analyze the 
association of the duration of the PSI with survival, patients were divided into 
quartiles according to their PSI. For multivariable analyses, Cox regression models 
with forward and backward stepwise selection (inclusion criterion: p-value of the 
score test ≤0.05, exclusion criterion: p-value of the likelihood ratio test ≥0.10) were 
used to analyze the possible impact of the following variables: age (continuous and 
categorical [3-8 vs. 8-13 vs. 13-18]), sex (categorical), stage (categorical: M0 vs. M1 
vs. M2/3 vs. incomplete staging; M0/1 vs. M2/3 vs. incomplete staging; M0 vs. M1/2/3 
vs. incomplete staging), histological subtype (categorical, classic vs. desmoplastic vs. 
large cell/anaplastic), residual tumor (categorical), therapy arm (categorical), PSI 
(continuous and categorical [group]), c-myc mRNA expression (categorical [≤1 vs. >1 
vs. no value available]), and TrkC mRNA expression (categorical [≤1 vs. >1 vs. no 
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value available]). For Cox regression, p-values of likelihood ratio test were calculated. 
In order to assess potential associations between the patient characteristics and PSI, 
the log-rank test was used. To compare the frequency of symptoms between different 
patient groups divided according to categorical age or metastatic stage, Fisher’s 
exact test was used. All p-values were considered as explorative, no significance 
level was fixed. Analyses were performed with SPSS software, version 16.0.
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3. RESULTS 
 
3.1. Patient and disease characteristics and presenting symptoms 
 
Patient and disease characteristics of the 224 study patients are summarized in 
Table 1. The most frequent presenting symptoms were headache, vomiting, ataxia, 
diplopia/squint, and vertigo/dizziness (Table 2). Headache and vertigo/dizziness were 
more frequently recorded in older (≥7 year-old) children, whereas ataxia was more 
prevalent in younger (<7 year-old) children (p<0.05). No association was found 
between the frequency of any symptom and the metastatic stage.  
 
3.2. Association of prediagnostic symptomatic interval with clinical and biological 
patient and disease characteristics 
 
The median PSI of all patients was 2.0 months (range, 0.1 - 48.0 months; 
interquartile range, 1.0 - 3.0 months) (Table 3, Figure 1). The two clinical factors 
displaying the strongest statistical association with PSI were metastasis stage and 
age: Patients with lower-stage disease and patients with older age at diagnosis had 
longer PSIs than those with higher-stage disease (p=0.075, Figure 2) or younger age 
(p=0.009, Figure 3), respectively. No association was found between PSI and sex, 
completeness of resection, or histological subtype. Patients with a higher c-myc 
mRNA expression level had a trend towards a higher PSI (p=0.085), no association 
was found between PSI and TrkC mRNA level. Apart from vomiting, which was 
associated with a shorter PSI (p=0.028), no associations were found between PSI 
and other symptoms (Table 3).  
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3.3. Survival probabilities according to prediagnostic symptomatic interval and other 
clinical factors 
 
Survival rates were slightly higher in the group with the longest PSI (Table 4, Figure 
4). When the patient group with the longest PSI (4.0 – 48.0 months) was compared to 
those with a shorter PSI (0 – 3.9 months), 10-year PFS probabilities were 66 and 
56%, respectively (p=0.202), and 10-year OS probabilities were 71% and 61%, 
respectively (p=0.056). When only patients with M0 were analyzed, a similar result 
was found. Survival probabilities according to other factors are summarized in Table 
4. 
 
In a multivariable Cox-regression analysis, forward and backward stepwise selection 
both identified lower age at primary surgery, higher metastatic stage at diagnosis, 
and 'sandwich' therapy arm as independent risk factors for lower PFS and OS 
probabilities. Higher expression of c-myc mRNA and lower expression of TrkC mRNA 
were retained in the backward selection only. In accordance to univariable analysis, 
longer duration of PSI was not shown to be associated with adverse outcome.
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4. DISCUSSION 
 
Due to its rarity and the non-specificity of symptoms and signs, childhood cancer 
frequently poses a major diagnostic challenge. This often results in PSIs in the range 
of several weeks to months.5-9, 11, 15, 28-30 Both the symptoms and the uncertainty of 
their origin can contribute to significant stress and suffering in patients and their 
parents/carers.12 Patients and physicians often speculate on whether an earlier 
diagnosis would have led to a less advanced disease stage and ultimately to a better 
prognosis, and alleged delay in diagnosis is a frequent source of medical malpractice 
lawsuits.13-14 However, published data on the effect of the PSI on the outcome in 
children with brain tumors and specifically medulloblastomas are still limited and 
inconclusive. 
 
To study the association of the PSI with disease stage at diagnosis, tumor control 
and survival outcome, we analyzed prospectively collected data on 224 well-
documented patients with medulloblastoma aged 3 - 18 years at diagnosis treated 
within the multicenter trial HIT’91.2 Median PSI of 2.0 months (range, 0.1 - 48.0 
months) as well as nature and prevalence of the presenting symptoms and signs 
were comparable to those in other series.4-8, 11, 15, 18, 20, 23 Contrary to common belief 
that a longer PSI is associated with more extensive disease, we found that patients 
with metastatic disease at presentation had a shorter median PSI than those without 
metastases (1.0 month vs. 2.0 months, p = 0.094). These results are in accordance 
with data by Halperin et al., who retrospectively analyzed 108 patients with 
medulloblastoma, in whom they found a median PSI of 8 weeks in patients with low-
stage disease and of 4 weeks in those with high-stage disease.6 A retrospective 
analysis of 166 patients with medulloblastoma by Brasme et al. found similar results 
 10
with a median PSI of 2 months (range, 0 - 15 months). To correlate PSI with tumor 
control and survival outcome, we compared survival probabilities of patients with 
longer PSIs (i.e. ≥4 months) with those of patients with shorter PSI. Interestingly we 
did not find an impaired prognosis in patients with the longest PSI, on the contrary, 
these patients had a tendency towards a superior outcome regarding overall survival 
(10-year OS 71% vs. 61%, p=0.056). Whereas the series published by Halperin et al. 
did not report any survival data, Kukal et al. found a significantly better progression-
free and overall survival rate in the patient group with the longest PSI when 
combining all brain tumor histologies. No difference in survival according to PSI 
within any subgroup of uniform histology, including within the 57 patients with 
medulloblastoma, was found. However, this study had several limitations (small 
patient number, retrospective data collection, heterogeneity of patient, disease and 
treatment characteristics, and prolonged period of patient enrollment). 
 
As in some studies the presence of post-operative residual tumor is an independent 
risk factor for tumor progression and death in patients with non-metastatic disease,31 
we hypothesized that a longer PSI may lead to a compromised resectability in this 
patient group. However, we could not detect any difference in PSI between those 
patients with any residual tumor and those without. Setting the cut-off to a residual 
tumor size of 1.5 cm2 yielded similar results. 
 
These results may seem counterintuitive, as one might expect longer PSIs to be 
associated with inferior survival, possibly caused by a more advanced disease stage 
by the time of diagnosis and/or a lower rate of gross-total tumor resection achieved. 
The association of a longer PSI with a lower metastatic stage and the trend towards a 
better progression-free and overall survival outcome are most probably explained by 
 11
the biology of the disease. Medulloblastoma comprises a group of biologically highly 
heterogeneous diseases displaying a broad variability of clinical behavior.27, 32-35 
Aggressive tumor growth may lead to more rapid clinical deterioration and hence to 
diagnosis within a shorter time period as compared to tumors with less aggressive 
growth characteristics. We could not find an association between PSI duration and 
histological subtype in our series, which however could be explained by the small 
patient number with non-classic histology. Apart from histology, other biologic 
markers are of known prognostic significance in medulloblastoma.27, 36-38 When 
comparing the PSIs of those patients with high c-myc mRNA expression (a negative 
prognostic marker) to those with lower expression, we found a trend towards a 
shorter PSI in those patients with higher c-myc expression (p=0.073), supporting to a 
certain degree our hypothesis that a biologically more aggressive disease may 
translate into a shorter PSI. A corresponding trend could not be demonstrated for 
TrkC mRNA expression. As c-myc and N-myc DNA amplification27 were only present 
in 5 patients each, we did not consider any corresponding analysis meaningful. 
These results however do not disprove the hypothesis that tumor biology may explain 
these counterintuitive results, as our analyses were limited by relatively small patient 
numbers with non-classic histology or available tissue for molecular analyses, and 
furthermore, histological subtype and c-myc/TrkC mRNA expression levels constitute 
only a small part of biological markers related to aggressiveness of disease. 
 
In our series older children and adolescents had longer PSIs than younger ones. This 
is in accordance with other studies of children with brain tumors or other neoplasms.6-
8, 15, 20, 23 A possible explanation is the association of younger age with more 
aggressive tumor biology, but also increased awareness of parents for health 
changes in smaller children, higher frequency of routine medical consultations at 
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young age, or dissimulation of symptoms in adolescence may contribute to this 
finding. In accordance with other series,6-7, 11 we could not detect an association of 
gender with PSI. 
 
Our study has several strengths: To our knowledge this is the largest and the only 
prospective study addressing the question whether the PSI is associated with stage 
at diagnosis and outcome in pediatric patients with medulloblastoma or any other 
brain tumor disease of homogeneous histology. Our patient population, which 
constitutes a representative sample of same-aged patients with medulloblastoma 
diagnosed at that time39 is well defined in terms of patient, disease, and treatment 
characteristics, with complete disease staging (including spinal MRI and CSF 
cytology) for most and central histopathological review available for all patients (an 
analysis of all 266 [95%] patients with available PSI value regardless of the 
availability of a central histopathological review yielded similar results). In addition, it 
is the first study evaluating the influence of biological markers on PSI in pediatric 
brain tumor patients. A limitation of our study is the lack of neurological, 
neuropsychological, and quality of life outcome information. One might for instance 
speculate that in a subgroup of patients with obstructive hydrocephalus a longer 
exposure to intracranial hypertension before diagnosis could lead to an adverse 
neuropsychological outcome.40 As only recently medulloblastoma trials have started 
prospectively collecting neuropsychological and quality of life outcome data, such 
issues may be addressed in the future. A further limitation, which applies to all PSI 
studies, is the lack of an objective measure of the PSI duration. We believe that the 
judgment of the treating oncologist based on clinical history and examination(s), as 
used in our analysis, is the best estimate of the true PSI. We cannot exclude under- 
or overestimations of the PSI in individual patients. However, the possibility of recall 
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bias was minimized by the prospective nature of data collection, as the case report 
forms were completed at enrollment in the trial. Another limitation is the incomplete 
number of tumor samples available for expression analysis of c-myc and TrkC 
mRNA, and the lack of data on beta-catenin status, one of the best characterized 
biological prognostic factors in medulloblastoma.38 Future trials incorporating tumor 
material collection for biological studies are warranted to further explore such 
correlations.  
 
In conclusion, a longer PSI was associated with lower metastatic stage at 
presentation and a trend towards higher progression-free and overall survival 
probabilities. These findings may help to reassure parents or physicians, who are 
often concerned about the question whether an earlier diagnosis would have resulted 
in a better prognosis, and they may be of use in the context of medical malpractice 
accusations. Nevertheless they certainly do not contradict the importance of a timely 
diagnosis, as uncertainty and prolonged symptoms can be difficult to tolerate and as 
any negative effects of a diagnostic delay on neurological, neuropsychological, or 
quality of life outcome cannot be excluded. Furthermore, in an individual patient a 
diagnostic delay can result in dismal outcome, for instance through life-threatening 
complications of intracranial hypertension. This underscores the paramount 
importance of an early diagnosis of pediatric brain tumor disease.  
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TABLES AND FIGURES 
 
Table 1: Patient and disease characteristics 
 
Number of patients 224
 
Age (median, range) 7.5 (2.9 – 17.5) years
 
Follow-up time of survivors (median, range) 11.8 (1.9 – 17.3) years
 
Gender 
 Male 143 (64%)
 Female 81 (36%)
 
Histological subtype 
 Classic 204 (91%)
 Desmoplastic 15 (7%)
 Large cell/anaplastic     5  (2%)
  
c-myc mRNA expression 
 ≤1 46 (21%)
 >1 51 (23%)
 No value available 127 (57%)
 
TrkC mRNA expression 
 ≤1 77 (34%)
 >1 20 (9%)
 No value available 127 (57%)
 
c-myc/TrkC mRNA expression 
 ≤1/>1 7 (3%)
 >1/≤1 38 (17%)
 Others 52 (23%)
 No value available 127 (57%)
 
Stage  
 M0 111 (50%)
 M1 33 (15%)
 M2/3 40 (18%)
 Incomplete staging 40 (18%)
  
Residual tumor 
- all patients 
 No 163 (73%)
 Yes   61 (27%)
- only patients with M0 
 No    80 (72%)
 Yes    31 (28%)
          - thereof with size ≥1.5 cm2 6 (5%)
 
Postoperative treatment 
 'Sandwich' 125 (56%)
 'Maintenance'   99 (44%)
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Table 2: Presenting symptoms 
 
Symptom All patients  
(n=224) 
Patients <7 
years 
at diagnosis
(n= 87) 
Patients ≥7 
years  
at diagnosis
(n=137) 
p-valuea 
 Number 
(percentage) 
Number 
(percentage)
Number 
(percentage)
 
Headache 125 (56%) 37 (43%) 88 (64%) 0.002
Vomiting 
(±nausea) 
125 (56%) 54 (62%) 71 (52%) 0.167
Ataxia 48 (21%) 27 (31%) 21 (15%) 0.007
Diplopia/squint 15 (7%) 5 (6%) 10 (7%) 0.787
Vertigo/dizziness 13 (6%) 1 (1%) 12 (9%) 0.018
Head tilt 6 (3%) 1 (1%) 5 (4%) -
Fatigue 5 (2%) 2 (2%) 3 (2%) -
Somnolence/loss 
of 
consciousness 
4 (2%) 0 (0%) 4 (3%) -
Nausea (without 
vomiting) 
3 (1%) 0 (0%) 3 (2%) -
Visual symptoms 
(NOS or other 
than 
diplopia/squint) 
3 (1%) 1 (1%) 2 (2%) -
Cervical pain 2 (1%) 2 (2%) 0 (0%) -
Concentration 
impairment 
2 (1%) 0 (0%) 2 (2%) -
Facial nerve 
paralysis 
2 (1%) 1 (1%) 1 (1%) -
Abdominal pain 1 (<1%) 1 (1%) 0 (0%) -
Abnormal weight 
gain 
1 (<1%) 1 (1%) 0 (0%) -
Back pain 1 (<1%) 1 (1%) 0 (0%) -
Constipation 1 (<1%) 1 (1%) 0 (0%) -
Leg weakness 1 (<1%) 1 (1%) 0 (0%) -
Night sweats 1 (<1%) 0 (0%) 1 (1%) -
Rapid growth of 
head 
1 (<1%) 1 (1%) 0 (0%) -
Seizure 1 (<1%) 1 (1%) 0 (0%) -
Slurred speech 1 (<1%) 0 (0%) 1 (1%) -
Tinnitus 1 (<1%) 0 (0%) 1 (1%) -
aFisher’s exact test (only for symptoms with a prevalence of ≥5%)  
NOS, not otherwise specified 
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Table 3: Prediagnostic symptomatic interval in relation to age, gender, histology, c-myc and TrkC 
mRNA expression, stage, postoperative residual tumor status, and presenting symptoms 
 
 PSI [months] 
median (range) 
p-value (log-rank test) 
   
All patients (n=224) 2.0 (0.1 – 48.0)  
    
Age at diagnosis  0.009 
 3 to 8 years (n=127)  1.0 (0.1 – 48.0)  
 8 to 13 years (n=64) 2.0 (0.1 – 48.0)  
 13 to 18 years (n=33) 3.0 (0.5 – 48.0)  
   
Gender  0.223 
 Male (n=143) 1.0 (0.1 – 48.0)  
 Female (n=81) 2.0 (0.1 – 48.0)  
   
Histological subtype  0.220 
 Classic (n=204) 2.0 (0.1 – 48.0)  
 Desmoplastic (n=15) 1.0 (0.5 – 7.0)  
 Large cell/anaplastic (n=5) 1.0 (0.3 – 3.0)  
    
c-myc mRNA expression  0.073  
 ≤1 (n=46) 2.0 (0.1 – 24.0)  with available value only: 
 >1 (n=51) 1.0 (0.1 – 6.0)  0.085 
 No tissue available for analysis (n=127) 2.0 (0.3 – 48.0)  
   
TrkC mRNA expression  0.283 
 ≤1 (n=77) 2.0 (0.1 – 15.0)  with available value only: 
 >1 (n=20) 1.0 (0.1 – 24.0)  0.747 
 No tissue available for analysis (n=127) 2.0 (0.3 – 48.0)  
   
Stage  0.145 
 M0 (n=111) 2.0 (0.1 – 48.0)  complete staging only: 
 M1 (n=33) 2.0 (0.3 – 9.0)  0.075 
 M2/3 (n=40) 1.0 (0.3 – 6.0)    M0/1 vs. M2/3: 
 Incomplete staging (n=40) 1.0 (0.1 – 48.0)    0.025 
   
Residual tumor   
- all patients, residual any size  0.595 
 No (n=163) 1.5 (0.1 – 48.0)  
 Yes (n=61) 2.0 (0.3 – 15.0)  
- only M0, residual any size  0.495 
 No (n=80) 1.0 (0.1 – 48.0)  
 Yes (n=31) 2.0 (0.5 – 15.0)  
- only M0, residual ≥1.5 cm2  0.605 
 No (n=105) 2.0 (0.1 - 48.0)  
 Yes (n=6) 3.0 (2.0 – 5.0)  
   
Presenting symptoma   
 Headache   0.685 
  present (n=125) 1.0 (0.1 – 48.0)  
  absent (n=99) 2.0 (0.1 – 15.0)  
   
 Vomiting   0.028 
  present (n=125) 1.0 (0.3 – 48.0)  
  absent (n=99) 2.0 (0.1 – 48.0)  
   
 Ataxia  0.100 
 19
  present (n=48)  1.0 (0.1 – 15.0)  
  absent (n=176) 2.0 (0.1 – 48.0)  
   
 Diplopia/squint   0.916 
  present (n=15) 2.0 (0.3 – 9.0)  
  absent (n=209) 2.0 (0.1 – 48.0)  
   
 Vertigo/dizziness   0.501 
  present (n=13)  3.0 (0.3 – 8.0)  
  absent (n=211) 2.0 (0.1 – 48.0)  
   
aOnly symptoms with a prevalence of ≥5%. PSI, prediagnostic symptomatic interval 
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Table 4: Survival probabilities according to prediagnostic symptomatic interval and other clinical and 
biological factors 
 
 10-year PFS 
(SE) [%] 
p-value (log-rank 
test) 
10-year OS 
(SE) [%] 
p-value (log-rank 
test) 
     
All patients (n=224)     
 58 (3)  63 (3)  
     
PSI   0.505  0.244 
 0 – 0.9 months (n=40) 63 (8)  64 (8)  
 1.0 – 1.9 months (n=70) 55 (6)  63 (6)  
 2.0 – 3.9 months (n=66) 54 (6)  57 (6)  
 4.0 – 48.0 months (n=48) 66 (7)  71 (7)  
     
PSI, only patients with M0  0.741  0.304 
 0 – 0.9 months (n=19) 68 (11)  72 (11)  
 1.0 – 1.9 months (n=32) 68 (8)  75 (8)  
 2.0 – 3.9 months (n=34) 61 (9)  64 (8)  
 4.0 – 48.0 months (n=26) 73 (9)  80 (8)  
     
Age at diagnosis  0.070  0.036 
 3 to 8 years (n=127)  53 (5)  60 (4)  
 8 to 13 years (n=64) 58 (6)  61 (6)  
 13 to 18 years (n=33) 79 (7)  81 (7)  
     
Gender  0.680  0.532 
 Male (n=143) 58 (4)  64 (4)  
 Female (n=81) 59 (6)  61 (6)  
     
Histological subtype  0.953  0.934 
 Classic (n=204) 58 (4)  62 (4)  
 Desmoplastic (n=15) 67 (12)  66 (12)  
 Large cell/anaplastic (n=5) 60 (22)  80 (18)  
     
c-myc mRNA expression  0.120  0.438 
 ≤1 (n=46) 70 (7)  with available 72 (7)  with available 
 >1 (n=51) 53 (7)  value only:  59 (7)  value only: 
 No value available (n=127) 57 (5)  0.041 62 (4)  0.191 
     
TrkC mRNA expression  0.376  0.218 
 ≤1 (n=77) 57 (6)  with value only: 61 (6)  with value only: 
 >1 (n=20) 75 (10)  0.172 80 (9)  0.079 
 No value available (n=127) 57 (5)  62 (4)  
     
Stage  0.021  0.007 
 M0 (n=111) 67 (5)   72 (4)  
 M1 (n=33) 54 (9)  54 (9)  
 M2/3 (n=40) 42 (8)  45 (8)  
 Incomplete staging (n=40) 54 (8)  64 (8)  
     
Residual tumor     
- all patients, residual any size  0.135  0.241 
 No (n=163) 60 (4)  65 (4)  
 Yes (n=61) 54 (6)  59 (6)  
- only M0, residual any size  0.667  0.987 
 No (n=80) 67 (5)  71 (5)  
 Yes (n=31) 68 (8)  74 (8)  
- only M0, residual ≥1.5 cm2  0.822  0.932 
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 No (n=105) 66 (5)  71 (5)  
 Yes (n=6) 83 (15)  83 (15)  
     
Postoperative treatment  0.034  0.016 
 'Sandwich' (n=125) 51 (5)  57 (5)  
 'Maintenance' (n=99) 67 (5)  71 (5)  
     
OS, overall survival rate; PFS, progression-free survival rate; PSI, prediagnostic symptomatic interval; SE, 
standard error 
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FIGURE LEGENDS 
 
Figure 1: Cumulative distribution of the prediagnostic symptomatic interval for all 224 
patients with medulloblastoma 
 
Figure 2: Cumulative distributions of the prediagnostic symptomatic intervals in all 
224 patients with medulloblastoma according to disease stage (M0, no metastases; 
M1, only microscopic cerebrospinal fluid metastases; M2/M3, macroscopic cerebral 
and/or spinal metastases) for those 184 patients with complete staging (M0 vs. M1 
vs. M2/M3, p=0.075; M0 vs. M1/M2/M3, p=0.025; log-rank test) 
 
Figure 3: Cumulative distributions of the prediagnostic symptomatic intervals 
according to the age groups at diagnosis for all 224 patients with medulloblastoma 
(p=0.009, log-rank test) 
 
Figure 4: Overall survival (OS) probabilities for all 224 patients with medulloblastoma 
according to the prediagnostic symptomatic interval (PSI): 10-year OS for PSI of 0 to 
0.9 months (group1), 64%; 1.0 to 1.9 months (group 2), 63%; 2.0 to 3.9 months 
(group 3), 57%; 4.0 to 48.0 months (group 4), 71% (p=0.244, log-rank test).  
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